Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
gptkb:parathyroid_hormone
|
| gptkbp:chemicalFormula |
C151H246N42O42S
|
| gptkbp:clinicalTrials |
Phase 3
|
| gptkbp:contraindication |
hypersensitivity to the drug
|
| gptkbp:date |
FDA_approved
|
| gptkbp:developedBy |
gptkb:OPKO_Health,_Inc.
|
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO 4900
|
| gptkbp:lastProduced |
2019
|
| gptkbp:marketedAs |
brand name
|
| gptkbp:route |
subcutaneous injection
|
| gptkbp:sideEffect |
headache
nausea injection site reactions |
| gptkbp:triggerType |
stimulates bone and kidney function
|
| gptkbp:usedFor |
treatment of hypoparathyroidism
|